220 related articles for article (PubMed ID: 24382018)
1. Management of ED under the "severe distress" criteria in the NHS: a real-life study.
Mohee A; Bretsztajn L; Storey A; Eardley I
J Sex Med; 2014 Apr; 11(4):1056-1062. PubMed ID: 24382018
[TBL] [Abstract][Full Text] [Related]
2. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
[TBL] [Abstract][Full Text] [Related]
4. A systematic review assessing the economic impact of sildenafil citrate (Viagra) in the treatment of erectile dysfunction.
Martin AL; Huelin R; Wilson D; Foster TS; Mould JF
J Sex Med; 2013 May; 10(5):1389-400. PubMed ID: 23347555
[TBL] [Abstract][Full Text] [Related]
5. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
[TBL] [Abstract][Full Text] [Related]
6. Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management.
Scranton RE; Goldstein I; Stecher VJ
J Sex Med; 2013 Feb; 10(2):551-61. PubMed ID: 23153075
[TBL] [Abstract][Full Text] [Related]
7. Erectile dysfunction and the drugs to treat it. In many cases, medications are all a man needs to stay sexually active.
Harv Health Lett; 2014 May; 39(7):7. PubMed ID: 25073193
[No Abstract] [Full Text] [Related]
8. Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study.
Fusco F; Sicuteri R; Rossi A; Kontodimas S; Haro JM; Imbimbo C; Mirone V;
Asian J Androl; 2009 Sep; 11(5):629-37. PubMed ID: 19701217
[TBL] [Abstract][Full Text] [Related]
9. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G
J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626
[TBL] [Abstract][Full Text] [Related]
10. Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction.
Doggrell SA
Expert Opin Pharmacother; 2005 Jan; 6(1):75-84. PubMed ID: 15709885
[TBL] [Abstract][Full Text] [Related]
11. Data on the utilization of treatment modalities for ED in Taiwan in the era of PDE5 inhibitors.
Tsai WK; Jiann BP
Int J Impot Res; 2014; 26(4):141-5. PubMed ID: 24451166
[TBL] [Abstract][Full Text] [Related]
12. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
[TBL] [Abstract][Full Text] [Related]
13. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction.
Jannini EA; Isidori AM; Gravina GL; Aversa A; Balercia G; Bocchio M; Boscaro M; Carani C; Corona G; Fabbri A; Foresta C; Forti G; Francavilla S; Granata AR; Maggi M; Mansani R; Palego P; Spera G; Vetri M; Lenzi A;
J Sex Med; 2009 Sep; 6(9):2547-60. PubMed ID: 19570039
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS).
Martin-Morales A; Haro JM; Beardsworth A; Bertsch J; Kontodimas S;
Eur Urol; 2007 Feb; 51(2):541-50; discussion 550. PubMed ID: 17084518
[TBL] [Abstract][Full Text] [Related]
15. The Global Online Sexuality Survey (GOSS): the United States of America in 2011 chapter II: phosphodiesterase inhibitors utilization among English speakers.
Shaeer O
J Sex Med; 2013 Feb; 10(2):532-40. PubMed ID: 23088586
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.
Corona G; Mondaini N; Ungar A; Razzoli E; Rossi A; Fusco F
J Sex Med; 2011 Dec; 8(12):3418-32. PubMed ID: 21995676
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction.
Kamenov ZA
J Sex Med; 2011 Mar; 8(3):851-64. PubMed ID: 21143421
[TBL] [Abstract][Full Text] [Related]
18. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
[TBL] [Abstract][Full Text] [Related]
19. Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance.
Ljunggren C; Hedelin H; Salomonsson K; Ströberg P
J Sex Med; 2008 Feb; 5(2):469-75. PubMed ID: 18086159
[TBL] [Abstract][Full Text] [Related]
20. A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction.
El-Meliegy A; Rabah D; Al-Mitwalli K; Mostafa T; Hussein T; Istarabadi M; Lei Y; Gurbuz S
Curr Med Res Opin; 2013 Jun; 29(6):707-17. PubMed ID: 23540436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
